FROM GRASSROOTS TO THE LAB
Our Mission
Since 1994 we have strived to build a world in which living in remote areas, discrimination, poverty, and conflict play no role in who has the right to access treatment for TB and HIV.
We partner with local people and national institutions.
Local healthcare workers are at the heart of our work.
Since our founding in 1994 we work with communities and national programs to ensure those in need receive the healthcare they deserve today and that it is sustainable for tomorrow.
Building supportive partnerships with individuals, families, communities, national health systems and international agencies underlie the development of our innovative approaches, which are scaled-up within countries and replicated around the world.
We take aim at root causes through a holistic approach to care.
GHC works with families, communities, local healthcare workers, and national programs to create a holistic approach to care. By building: home-, community-, and hospital-based treatment centers people can receive TB and HIV care wherever they are.
We ensure that basic needs such as food and transportation are never barriers to TB and HIV care so no one has to choose between working to eat and seeking care for TB or HIV. Our flexible approach and national partnerships seek to solve problems and never leave anyone behind.
We create Centers of Excellence within hospitals working with national programs, lending our expertise to establish the best practices that are sustainable for treating people afflicted by TB and HIV.
We nest patient-centered research and documentation in our delivery of care networks
Our work has successfully influenced WHO recommendations and international approaches to enhance TB-HIV and drug-resistant TB (DR-TB) treatment worldwide.
Our community-based approaches in Cambodia such as: incorporating patient supporters in TB treatment—first done for refugees seeking treatment for TB on the Thai-Cambodian border war zone; food delivery with TB treatment that CHC pioneered with the Work Food Program; and the initiation of TB and DR-TB treatment at home and with community support, have influenced global TB and TB/HIV care over the past 30 years.
Our patient centered lab-based science has unveiled how TB infection and TB/HIV co-infection interacts with the immune system, and defined predictive markers of effective immunity or inflammation, suggesting new approaches for diagnosis and care
In 2011, the success of CHC’s collaborative research with the NIH, ANRS, Institut Pasteur du Cambodge and the Cambodian National AIDS and TB programs research on TB/HIV treatment provided the evidence for the World Health Organization to change its recommendations on how to treat TB-HIV co-infection, which is estimated to have saved ~1,000,000 lives (nearly 150,000 lives globally per year) since that time.
GHC’s participation as an international clinical site in the MRC Clinical Trials Unit- and Union-led STREAM trial in Ethiopia contributed to showing that a new regimen of drugs for DR-TB could shorten treatment from 2 years to 9-12 months, and with the addition of bed aquiline, could be accomplished with an all oral DR-TB drug regimen, game changers in treatment of DR-TB.
Delete this block?
Girls in a computer class at CHC’s Maddox Chivan Children’s Center for HIV-infected and affected children in Phnom Penh.
HEALING
UNEQUAL ACCESS
A young mother hospitalized for treatment Drug Resistant TB in Ethiopia